Eltrombopag: The discovery of a second generation thrombopoietin-receptor agonist

Expert Opinion on Drug Discovery

Volumn 4, Issue 1, 2009, Pages 85-93

  Stasi, Roberto ^a  

^a REGINA APOSTOLORUM HOSPITAL   (Italy)

Author keywords

Agonist; Eltrombopag; Megakaryocytes; Platelets; Receptor; Thrombocytopenia; Thrombopoietin

Indexed keywords

ELTROMBOPAG; JANUS KINASE 2; PEGINTERFERON; PLACEBO; RIBAVIRIN; STAT5 PROTEIN; THROMBOPOIETIN RECEPTOR;

BONE MARROW CELL; CATARACT; CELL DIFFERENTIATION; CELL PROLIFERATION; CHIMPANZEE; CLINICAL TRIAL; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; HEADACHE; HEPATITIS C; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IN VITRO SELECTION; LIVER TOXICITY; MAMMAL CELL; MEGAKARYOCYTE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS;

EID: 67649094956     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460440802642484     Document Type: Review

References (57)

1. Choi ES, Hokom MM, Chen JL, et al. The role of megakaryocyte growth and development factor in terminal stages of thrombopoiesis. Br J Haematol 1996;95:227-233 (Pubitemid 26360207)
2. Gordon MS, Mccaskill-stevens WJ, Battiato LA, et al. A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 1996;87:3615-3624 (Pubitemid 26129589)
3. Tepler I, Elias L, Smith JW 2nd, et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996;87:3607-3614
4. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002;100:3457-3469 (Pubitemid 35303910)
5. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001;98:3241-3248
6. Kuter DJ. New thrombopoietic growth factors. Blood 2007;109:4607-16 •• A comprehensive review about thrombopoietic agents.
7. Evangelista ML, Amadori S, Stasi R. Biologic aspects of thrombopoietin and the development of novel thrombopoietic agents for clinical use. Current drug discovery technologies 2007;4:162-73 •• An exhaustive review about the biology of thrompobopoietin and the development of thrombopoietic agents.
8. Vigon I, Mornon JP, Cocault L, et al. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci USA 1992;89:5640-5644
9. Skoda RC, Seldin DC, Chiang MK, et al. Murine c-mpl: a member of the hematopoietic growth factor receptor superfamily that transduces a proliferative signal. EMBO J 1993;12:2645-2653 (Pubitemid 23218313)
10. Le Coniat M, Souri M, Vigon I, et al. The human homolog of the myeloproliferative virus maps to chromosome band 1p34. Hum genet 1989;83:194-196 (Pubitemid 19234572)
11. Alexander WS, Dunn AR. Structure and transcription of the genomic locus encoding murine c-Mpl, a receptor for thrombopoietin. Oncogene 1995;10:795-803
12. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990;87:6934-6938 (Pubitemid 20325179)
13. Mignotte V, Vigon I, Boucher de Crevecoeur E, et al. Structure and transcription of the human c-mpl gene (MPL). Genomics 1994;20:5-12 (Pubitemid 24100913)
14. Deveaux S, Filipe A, Lemarchandel V, et al. Analysis of the thrombopoietin receptor (MPL) promoter implicates GATA and Ets proteins in the coregulation of megakaryocyte-specific genes. Blood 1996;87:4678-4685 (Pubitemid 26162367)
15. Kiladjian JJ, Elkassar N, Hetet G, et al. Study of the thrombopoitin receptor in essential thrombocythemia. Leukemia 1997;11:1821-1826 (Pubitemid 27485125)
16. Li J, Sabath DF, Kuter DJ. Cloning and functional characterization of a novel c-mpl variant expressed in human CD34 cells and platelets. Cytokine 2000;12:835-844 (Pubitemid 30479464)
17. Debili N, Wendling F, Cosman D, et al. The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood 1995;85:391-401
18. Li J, Xia Y, Kuter DJ. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br J Haematol 1999;106:345-356 (Pubitemid 29450656)
19. Wolber EM, Jelkmann W. Thrombopoietin: the novel hepatic hormone. News Physiol Sci 2002;17:6-10
20. Alexander WS, Metcalf D, Dunn AR. Point mutations within a dimer interface homology domain of c-Mpl induce constitutive receptor activity and tumorigenicity. EMBO J 1995;14:5569-5578
21. Feese MD, Tamada T, Kato Y, et al. Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment. Proc Natl Acad Sci USA 2004;101:1816-1821 (Pubitemid 38228974)
22. Sabath DF, Kaushansky K, Broudy VC. Deletion of the extracellular membrane-distal cytokine receptor homology module of Mpl results in constitutive cell growth and loss of thrombopoietin binding. Blood 1999;94:365-367 (Pubitemid 29300171)
23. Erickson-Miller CL, Delorme E, Iskander M, et al. Species specificity and receptor domain interaction of a small molecule TPO receptor agonist [abstract 2909]. Blood 2004;104 •• This study shows that eltrombopag binds the transmembrane domain of the TPO-receptor of humans and chimpanzees, but not the TPO-receptor of other species.
24. Kim MJ, Park SH, Opella SJ, et al. NMR structural studies of interactions of a small, nonpeptidyl Tpo mimic with the thrombopoietin receptor extracellular juxtamembrane and transmembrane domains. J Biol Chem 2007;282:14253-14261 (Pubitemid 47100429)
25. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest 2005;115:3339-3347 (Pubitemid 43121817)
26. Livnah O, Stura EA, Middleton SA, et al. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science (NY) 1999;283:987-990 (Pubitemid 29100256)
27. Remy I, Wilson IA, Michnick SW. Erythropoietin receptor activation by a ligand-induced conformation change. Science (NY) 1999;283:990-993 (Pubitemid 129505219)
28. Tortolani PJ, Johnston JA, Bacon CM, et al. Thrombopoietin induces tyrosine phosphorylation and activation of the Janus kinase, JAK2. Blood 1995;85:3444-3451
29. Kaushansky K. Thrombopoietin and the hematopoietic stem cell. Ann NY Acad Sci 2005;1044:139-141
30. Ezumi Y, Takayama H, Okuma M. Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists-induced aggregation in platelets in vitro. FEBS Lett 1995;374:48-52
31. Stasi R, Evangelista ML, Amadori S. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Drugs 2008;68:901-12 • A review of the pharmacology of romiplostim and eltrombopag and the use of the novel thrombopoietic agents in ITP.
32. Erickson-Miller CL, Delorme E, Tian SS, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol 2005;33:85-93 •• A description of the laboratory investigations and preclinical strategies that lead to the development of eltrombopag.
33. Duffy KJ, Price AT, Delorme E, et al. Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 2. Rational design of naphtho[1,2-d]imidazole thrombopoietin mimics. J Med Chem 2002;45:3576-3578
34. Rojnuckarin P, Drachman JG, Kaushansky K. Thrombopoietin-induced activation of the mitogen-activated protein kinase (MAPK) pathway in normal megakaryocytes: role in endomitosis. Blood 1999;94:1273-1282 (Pubitemid 29380408)
35. Erickson-Miller C, Delorme E, Tian SS, et al. Preclinical activity of eltrombopag (SB-497115), an oral, non-peptide thrombopoietin Receptor Agonist. Stem Cells;In press •• A summary of the preclinical studies demonstrating the selective interaction of eltrombopag with the TpoR and the effects of eltrombopag on megakaryocyte differentiation in platelets.
36. Us Food and Drug Administration. 2008 Center for Drug Evaluation and Research (CDER) Meeting Documents. Oncologic Drugs Advisory Committee May 30, 2008. Available from: http://wwwfdagov/ohrms/dockets/AC/cder08html [Last accessed 15 October 2008]
37. Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007;109:4739-41 •• An investigation of the pharmacology of eltrombopag in healthy volunteers. (Pubitemid 46827766)
38. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:2237-47 •• A randomized, double-blind, placebo-controlled trial that showed the efficacy and safety of short-term treatment with eltrombopag.
39. Bussel J, Provan A, Shamsi T, et al. Eltrombopag raises platelet count and reduces bleeding compared with placebo during short-term treatment in chronic idiopathic thrombocytopenic purpura: a phase III study [abstract 0390]. Haematologica 2007;92(Suppl 1) • An analysis of the efficacy results of short-term treatment with eltrombopag in the TRA100773B trial.
40. Bussel JB, Cheng G, Saleh M, et al. Long-term safety and efficacy of oral eltrombopag for the treatment of idiopathic thrombocytopenic purpura (ITP) [abstract 0949]. Haematologica 2008;93 •• A preliminary analysis of adverse events and continued response during long-term dosing of eltrombopag.
41. Psaila B, Bussel JB, Vasey S, et al. Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic ITP [abstract 0294]. Haematologica 2008;93 •• A preliminary analysis of response patterns in patients with chronic ITP upon repeated administration of eltrombopag.
42. Mchutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007;357:2227-2236 (Pubitemid 350190753)
43. Gernsheimer T. Epidemiology and pathophysiology of immune thrombocytopenic purpura. Eur J Haematol Suppl 2008;3-8
44. George JN. Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemost 2006;4:1664-1672 (Pubitemid 44144790)
45. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-714
46. Sulkowski MS. Management of the hematologic complications of hepatitis C therapy. Clin Liver Dis 2005;9:601-616 (Pubitemid 41406390)
47. Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol 2000;95:2936-2939 (Pubitemid 30783222)
48. Roberts SA. High-throughput screening approaches for investigating drug metabolism and pharmacokinetics. Xenobiotica 2001;31:557-589 (Pubitemid 32826392)
49. Schwardt O, Kolb H, Ernst B. Drug discovery today. Curr Top Med Chem 2003;3:1-9
50. Muegge I. Selection criteria for drug-like compounds. Med Res Rev 2003;23:302-321 (Pubitemid 36457537)
51. Rees DC, Congreve M, Murray CW, Carr R. Fragment-based lead discovery. Nat Rev 2004;3:660-672 (Pubitemid 39173507)
52. Scheuermann J, Dumelin CE, Melkko S, Neri D. DNA-encoded chemical libraries. J Biotechnol 2006;126:568-581 (Pubitemid 44634823)
53. Kaushansky K. Hematopoietic growth factor mimetics. Ann NY Acad Sci 2001;938:131-138 (Pubitemid 32620025)
54. Cwirla SE, Balasubramanian P, Duffin DJ, et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 1997;276:1696-1699 (Pubitemid 27421976)
55. de Serres M, Ellis B, Dillberger JE, et al. Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB/c mice and New Zealand white rabbits: evaluation of the potential for thrombopoietin neutralizing antibody production in man. Stem Cells 1999;17:203-209 (Pubitemid 29350211)
56. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004;76:628-638 (Pubitemid 39601552)
57. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007;7:715-725 (Pubitemid 47327396)